CTCs can modulate NK cell anti-tumor activity through production of inhibitory cytokines (e.g., IL-1β, IL-8, IL-10, and prostaglandin E2) that block the NK cell immunoglobulin receptors (KIRs) [2,3] (Figure 3a). The gene discussed is IL1B; the disease is neoplasm.